There is a mark with the company logo outside the ELI Lilly headquarters in Indianapolis, Indiana, on March 17, 2024.
Scott Olson Gety pictures
Eli Lily On Thursday he said the highest dose of Daily obesity pills Patients have helped to lose approximately 12 % of body weight, or nearly 27 pounds, in 72 weeks in a late stage experience, which represents a way to enter the market.
Weight loss was 11.2 % when analyzing all patients regardless of stopping. The shares of the company fell by more than 12 % in the pre -market trade on Thursday.
The data comes under what some Wall Street analysts expected for ELI Lilly’s Oral GLP-1, with hopes for weight loss about 15 %.
Some doctors said that the results seem to be comparable, but in general it is slightly lower than the level of weight loss with Novo NordskGLP-1 injecting GLP-1 for obesity, Wiki. Some doctors also noticed the number of patients at the highest dose of birth control pills who stopped treatment due to side effects or any other experiment.
However, other doctors praised the results and pill capabilities to reach new patients, such as those who are afraid of needles.
“This is a strong promising result of an oral factor,” said Dr. Jaimi Al -Manduz, the medical director of the Weight Wellness program at the UT Southweestern Medical Center.
“The injection has placed a loud tape, but this study enhances the possibility of being the oral GLP-1 to be a transformative in obesity care, especially for patients who hesitate to start or maintain injections,” continued.
Dr. Mihil, “Micha” Zilbermint, hospital director at the endocrinologist at Johns Hopkins Community Doctors, said he believed the pill “has the ability to be a changing toys, as long as people can withstand side effects.”
The results of the experiment are among the most closely viewed pharmaceutical industry studies for this year, Positive data in April from the third stage experience Exercise testing experimental pills in diabetics. It brings ELI Lilly, or Forforglipron, one step until it becomes the first new alternative free of needle on the booming market for weight loss and the GLP-1S diabetes.
In an interview, Ken Kester, President of Lily Coldate Exiest, said in an interview, Ken Keter, President of Lily Coldate Ikestlist, said that Eli Lily is expected to provide organized data by the end of the year, with plans to launch birth control pills in 2026.
This launch may mainly change the space, which helps more patients reach treatments and reduce the current injection deficiency. The most convenient and easier birth control pills can help its manufacture in promoting their dominance in the growing part, such as other drug makers, including its main rival Novo Nordisk, in the birth control pill to the market.
Kester said that there are approximately 8 million patients with obesity drugs and injection diabetes, but it is likely that about 170 million patients can benefit from medications.
“In order to fulfill this request, we will need other options, including small molecules such as Orforglipron, which use different production means and does not also need advanced for the supply chain to distribute to patients,” he said.
Dr. Amy Sher, a professor of medicine and director of the University of Florida, said that she hopes that the birth control pills will be less expensive than the current injection, which is largely due to the devices they come in. She said that low prices can help eliminate barriers that prevent patients from reaching patients, which is likely to make them more willing to cover drugs.
Many insurance companies still do not cover the GLP-1S obesity. Wegovy and other drugs have a list prices approximately $ 1,000 before insurance.
Detailed experimental results
The highest dose of Eli Lili helped more than 59 % of patients lost at least 10 % of body weight and more than 39 % of patients lose at least 15 % of their weight, according to the results of the experiment.
Mandoz said that the percentage of people who achieved “greater sizes” of weight loss “is very impressive for an oral factor, adding that many people” often ignore the percentage of people who achieve these weight loss groups “and usually focus closely on the average weight loss.”
OrforiPron also helped reduce cardiovascular risk factors.
But data on the duration of some patients who endured the birth control pills in the experiment were subjected to some analysts’ estimates.
About 10.3 % of patients who took the highest dose of birth control pills – 36 milligrams – stop treatment due to side effects, compared to about 2.6 % of those who took the end. These side effects were mainly the digestive system, such as nausea and vomiting, and light to moderate in severity. About 24 % of those who took the highest dose of experienced, while 33.7 % and 23.1 % have nausea and diarrhea, respectively.
Before the data, the BMO Markets Evan Seigerman analyst said that it expects less than 10 % of patients at the highest dose of birth control pills to stop treatment due to side effects, low vomiting, nausea and diarrhea.
Dr. Caroline Abovian, the participating director of the weight and well-being center at Brigham Hospital and Women, said that more patients have stopped taking birth control pills due to side effects compared to the current GLP-1 in the market. Stopping rates due to side effects in the experiences of the late stage on Wegovy and Eli Lilly’s Weekly Ponsy Injility Zepbound About 7 % Or less.
She pointed out that nearly a quarter of patients with the highest dose of birth control pills have stopped treatment for any reason, with a warning that the enthusiasm for OrforiPron should be relieved “because we get all this excitement, then the pill comes out, and then no one can take it.”
It is unclear why, regardless of side effects, these patients have stopped birth control pills.
But the University of Florida said that she does not believe that stopping rates or side effects will be a decisive factor for doctors when prescribing birth control pills.
It believes that the oral option can make more doctors more comfortable in prescribing the GLP-1 patients. Sher added that some doctors are currently hesitating to describe the injection because they “may not know how to tell patients how to use them.”
The Manz said that the described decisions depend on the specific needs and preferences of the patient, as well as access and ability to withstand costs. The injection GLP-1 may be the preferred option for patients whose priority is a greater level of weight loss or those who suffer from great heart complications, or health problems arising from cardiovascular disease and metabolic disorders.
But oral GLP-1 can be the most appropriate for those who “give priority to simplicity or comfort or have these logistical challenges with injection.”
The detailed results of the experiment will be presented in September in a European medical meeting and published in the Journal of Laysee. More results of the third stage will be shared on the birth control pills later this year, including a study on obese or overweight adults and have type 2 diabetes.
Wegovy, Eli Lilly’s Pill, Orforglipron and Novo Nordisk works in Rybelsus by targeting the bowel hormone called GLP-1 to enhance weight loss and regulate blood sugar. But unlike these other medications, the Eli Lili pill is not a pill for peptide. This means that it is absorbed more easily in the body and does not require nutritional restrictions such as Rybelsus.
Elie Lily is currently about three years away from other drug makers who develop birth control pills, including Vizarand Astrazenecaand Rushand Treatment structure and Vicing treatmentsThe former Guggenheim Seamus Fernandez analyst CNBC.
Some analysts expect the value of the GLP-1 market more than $ 150 billion annually by the early thirties. Fernandez said the oral GLP-1 may grow for $ 50 billion in this total.
– CNBC from CNBC contributed to this report.
https://image.cnbcfm.com/api/v1/image/107388672-1710764847941-gettyimages-2092473213-dsc01895copy_8zcnfedn.jpeg?v=1754506606&w=1920&h=1080
Source link